期刊文献+

厄贝沙坦对冠状动脉性心脏病合并持续性心房颤动的临床观察 被引量:2

下载PDF
导出
摘要 目的观察厄贝沙坦联合胺碘酮对冠心病合并持续性心房颤动患者心律转复的影响。方法选择冠心病合并持续性心房颤动患者80例,随机分为两组。A组(40例)在冠心病常规治疗基础上加用胺碘酮治疗;B组(40例)在冠心病常规治疗的基础上加用胺碘酮、厄贝沙坦。随访一年,观察两组治疗前后左心房内径(LAD)、血清超敏C-反应蛋白(hs-CRP)变化及心房颤动转复率及维持率。结果 B组左房内径及心房颤动转复率及维持率明显优于A组(P<0.05);两组治疗后hs-CRP较治疗前均有下降,但B组优于A组(P<0.05)。结论厄贝沙坦联合胺碘酮在提高冠心病合并持续性心房颤动患者心律转复率,降低复发率,优于单独应用胺碘酮,并能有效降低血中hs-CRP水平。
出处 《中西医结合心脑血管病杂志》 2011年第7期779-781,共3页 Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease
  • 相关文献

参考文献11

  • 1黄宛,主编.临床心电图学[M].第5版.北京:人民卫生出版社,2003.19.
  • 2Turhan H, Aksoy Y, Yetkin E,et al. The impact of inflammation on the development, successful cardioversion, recurrence and/or perpetuation of atrial fibrillation[J]. Int J Cardiol, 2007,118 : 256- 257.
  • 3Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation[J]. Circulation,2006,114(7) :700 - 752.
  • 4Gaudino M, Andreotti F,Zamparelli R,et al. The 174G/C interleu- kin - 6 polymorphism influenees postoperative interleukin - 6 levels and postoperative atrial fibrillation. Is atrial fibrillation an inflam- matory complication[J]. Circulation, 2003,108 (Suppl) : 195 - 199.
  • 5Bruuins P, Velthius H, Yazdanbakhsh AP, et al. Activation of the complement system during and after cardiopulmonary by pass sur- gery. Post - surgery activation involves C - reactive protein and is associated with postoperative arrhythmia[J]. Circulation, 1997,96 (10) :3542 - 3548.
  • 6$ehifrin EL. Beyond Blood pressure:The endothdium and atherose lerosis progression[J]. Am J Hypertention, 2002,15 : 115.
  • 7Dernellis J,Panaretou M. Relationship between C - rective protein concentrations during glocueoryicoid therapy and recurrent atrial fibrillation[J]. Eur Heart J, 2004,25 (13) : 1100 - 1107.
  • 8Lopez B,Querejeta R,Varo N,et al. Usefulness of serum carboxy- terminal propepticle of procollagen type I in assessment of thecardioreparative ability of antihypertensive treatment in hyperten- sive patients[J]. Circulation, 2001,104 : 286 - 291.
  • 9Burstein B, Nattet S. Atrial fibrosis: Mechanisms and clinical rele' vance in atrial fibrillation [J]. J Am Coll Cardiol, 2008,51 : 802 -809.
  • 10Hideko N, Koickiro K, Hidenori U, eta 1. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation[J]. Circulation, 2000,101(2) :2613 - 2617.

共引文献6

同被引文献21

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部